⬤ Loading…
Altria Group, Inc.
…
S&P 500
🏹 Trader: 🎯 Near 52W High | BRS 75 Ready View all →
$120.6B
Market Cap
14.0
P/E
3.21
PEG
43.5%
ROCE
N/M
ROE
-7.45
D/E
76.2%
OPM
-2.8%
% from 52W High
67
α RS
🔍 MO is showing a multi-screen setup because it matches 11 of 39 tracked screener presets, Sector RRG has Consumer Staples in the Leading quadrant with the trail still strengthening, RS Rating is 67, and it has maintained a 20-day Near 52-Week High momentum persistence. The main caution: the Accumulation Zone preset's Backtest win rate is only 47.5%. Net: Mixed signal stack, not a recommendation. ? Conviction RRG RS Rating Momentum Streaks Backtest
Sources
Conviction 11/39 · Consumer Staples in Leading quadrant · RS Rating 67 · Near 52-Week High streak: 20d · Backtest win rate 47.5%
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for MO including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
— Excellent
— Good
— Average
— Poor
By Category
📊 Peer Medians
About

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. It offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and oral tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand. The company sells its products to distributors, as well as large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding MO
View All Superinvestors →
Manager Shares Value % of Fund Period
Jim Simons Renaissance Technologies LLC 1.68M $110.6M 0.17% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific → Stable 5 quarters Full tone analysis in Intelligence →
Good quarter Investor Presentation One-Pager? Q2 2026
Revenue
$6.1B
+0.1% YoY
Adjusted EPS
$1.48
+2.8% YoY
What Went Right
  • Smokable adjusted OCI grew 2.4% to $3.0B in Q2, with margin expansion to 64.8%.
  • on! PLUS expanded to 120,000 stores, driving on! retail share up 0.8 points sequentially.
  • Returned nearly $3.9B to shareholders in the first half via dividends and buybacks.
What to Watch
  • Oral tobacco adjusted OCI fell 8% YoY due to on! PLUS investments and tough prior-year comparables.
  • Consumer financial pressure persists, driving discount segment share growth and Marlboro share decline of 1.5 points YoY.
  • Illicit flavored disposable e-vapor products remain prevalent despite increased enforcement.
Management Guidance
  • FY26 adjusted EPS narrowed to $5.61-$5.72, implying 3.5%-5.5% growth from 2025 base of $5.42.
  • Expects higher export volume and duty drawback benefits in 2H, balanced across Q3 and Q4.
  • 2026 CapEx guidance raised to $375-$450 million, reflecting USSTC facilities consolidation.
Investor Lens
The thesis is incrementally stronger after this call. Smoke-free momentum is building with on! PLUS national expansion and an improving regulatory backdrop, while smokeable profitability remains robust with strong Marlboro pricing and disciplined portfolio management. However, persistent consumer weakness and near-term investments in oral tobacco create some uncertainty. The guidance raise signals management confidence in delivering the full-year plan.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📈 STRONG Q2 adjusted EPS $1.48 +2.8%, FY guidance raised to $5.61-$5.72.
Revenue
Net revenues were $6.11 billion, up 0.1% YoY, while revenues net of excise taxes rose 1.2% to $5.36 billion. Strong smokeable pricing offset softer oral tobacco volumes.
Profitability
Adjusted diluted EPS rose 2.8% to $1.48 in Q2, and first-half adjusted EPS grew 4.9% to $2.80. Reported diluted EPS was $1.37, down 2.8% YoY.
Margins
Smokable adjusted OCI margin expanded to 64.8% in Q2, while oral tobacco adjusted OCI margin remained high at 66.7%. Overall profitability was supported by Marlboro price realization.
Balance Sheet
Debt-to-EBITDA stood at 1.9x as of June 30, in line with the ~2x target. Q2 dividends totaled $1.8 billion and $665 million remained under the share repurchase program.
Key Risks
Management flagged persistent pressure on low-income consumers from elevated gas prices and inflation, driving discount share growth. Oral tobacco adjusted OCI fell 8% in Q2 due to investments in on! PLUS and difficult prior-year comparisons. Illicit disposable e-vapor products remain prevalent despite increased enforcement.
Outlook
FY26 adjusted EPS guidance was narrowed to $5.61-$5.72, implying 3.5%-5.5% growth from 2025's $5.42. Export/duty drawback benefits are expected to be more balanced across Q3 and Q4, and 2026 CapEx guidance was raised to $375-$450 million.
Generated by AI · Q2 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-07-30
Second quarter and first half results showed strong adjusted EPS and OCI growth, with robust performance in smokable and oral segments, increased shareholder returns, and improved regulatory clarity. Guidance for 2026 EPS was raised, while consumer and macroeconomic pressures remain key watchpoints.
Q1 2026 Q1 2026 2026-04-30
Adjusted EPS grew 7.3% in Q1, driven by strong smokable and oral tobacco performance, with Marlboro gaining premium share and ON! expanding nationally. Guidance for 2026 EPS is reaffirmed, reflecting balanced growth and macroeconomic uncertainty.
Q4 2025 Q4 2025 2026-01-29
Adjusted diluted EPS grew 4.4% in 2025, with $8B returned to shareholders and strong smoke-free portfolio progress. 2026 EPS guidance is $5.56–$5.72, with growth weighted to the second half and continued investment in import/export and smoke-free products.
Q3 2025 Q3 2025 2025-10-30
Q3 saw adjusted EPS up 3.6% and strong progress in smoke-free and adjacent growth, with on! PLUS launched and regulatory filings for heated tobacco. Dividend was raised, share repurchase expanded, and guidance for 2025 EPS was increased, despite ongoing regulatory and market challenges.
Q2 2025 Q2 2025 2025-07-30
Second quarter and first half results showed strong adjusted EPS and OCI growth, led by ON's performance and robust shareholder returns. Guidance for 2025 EPS was raised, with continued focus on smoke-free products, regulatory advocacy, and disciplined capital allocation.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.